Literature DB >> 30730851

Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.

Kelly L Singel1, Tiffany R Emmons1, Anm Nazmul H Khan2, Paul C Mayor3, Shichen Shen4, Jerry T Wong5, Kayla Morrell6, Kevin H Eng6, Jaron Mark3, Richard B Bankert7, Junko Matsuzaki8, Richard C Koya8, Anna M Blom9, Kenneth R McLeish10, Jun Qu4, Sanjay Ram11, Kirsten B Moysich12, Scott I Abrams1, Kunle Odunsi3,8, Emese Zsiros3,8, Brahm H Segal1,2,13.   

Abstract

Epithelial ovarian cancer (EOC) often presents with metastases and ascites. Granulocytic myeloid-derived suppressor cells are an immature population that impairs antitumor immunity. Since suppressive granulocytes in the ascites of patients with newly diagnosed EOC were morphologically mature, we hypothesized that PMN were rendered suppressive in the tumor microenvironment (TME). Circulating PMN from patients were not suppressive but acquired a suppressor phenotype (defined as ≥1 log10 reduction of anti-CD3/CD28-stimulated T cell proliferation) after ascites supernatant exposure. Ascites supernatants (20 of 31 supernatants) recapitulated the suppressor phenotype in PMN from healthy donors. T cell proliferation was restored with ascites removal and restimulation. PMN suppressors also inhibited T cell activation and cytokine production. PMN suppressors completely suppressed proliferation in naive, central memory, and effector memory T cells and in engineered tumor antigen-specific cytotoxic T lymphocytes, while antigen-specific cell lysis was unaffected. Inhibition of complement C3 activation and PMN effector functions, including CR3 signaling, protein synthesis, and vesicular trafficking, abrogated the PMN suppressor phenotype. Moreover, malignant effusions from patients with various metastatic cancers also induced the C3-dependent PMN suppressor phenotype. These results point to PMN impairing T cell expansion and activation in the TME and the potential for complement inhibition to abrogate this barrier to antitumor immunity.

Entities:  

Keywords:  Complement; Immunology; Neutrophils; Oncology; T cells

Mesh:

Substances:

Year:  2019        PMID: 30730851      PMCID: PMC6483507          DOI: 10.1172/jci.insight.122311

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  79 in total

1.  Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs.

Authors:  Stephan W Lindemann; Christian C Yost; Melvin M Denis; Thomas M McIntyre; Andrew S Weyrich; Guy A Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

2.  A novel method for direct measurement of complement convertases activity in human serum.

Authors:  A M Blom; E B Volokhina; V Fransson; P Strömberg; L Berghard; M Viktorelius; T E Mollnes; M López-Trascasa; L P van den Heuvel; T H Goodship; K J Marchbank; M Okroj
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

3.  Granule exocytosis contributes to priming and activation of the human neutrophil respiratory burst.

Authors:  Silvia M Uriarte; Madhavi J Rane; Gregory C Luerman; Michelle T Barati; Richard A Ward; William M Nauseef; Kenneth R McLeish
Journal:  J Immunol       Date:  2011-06-03       Impact factor: 5.422

4.  Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.

Authors:  Min Soon Cho; Rajesha Rupaimoole; Hyun-Jin Choi; Kyunghee Noh; Jichao Chen; Qianghua Hu; Anil K Sood; Vahid Afshar-Kharghan
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

5.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Takafumi Ikeda; Manabu Minami; Atsushi Kawaguchi; Toshinori Murayama; Masashi Kanai; Yukiko Mori; Shigemi Matsumoto; Shunsuke Chikuma; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Akihiko Ueda; Yuko Hosoe; Satoshi Morita; Masayuki Yokode; Akira Shimizu; Tasuku Honjo; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

6.  A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1.

Authors:  Janesh Pillay; Vera M Kamp; Els van Hoffen; Tjaakje Visser; Tamar Tak; Jan-Willem Lammers; Laurien H Ulfman; Luke P Leenen; Peter Pickkers; Leo Koenderman
Journal:  J Clin Invest       Date:  2011-12-12       Impact factor: 14.808

7.  Tumor cell-released autophagosomes (TRAP) enhance apoptosis and immunosuppressive functions of neutrophils.

Authors:  Rong Gao; Jie Ma; Zhifa Wen; Peiying Yang; Jinjin Zhao; Meng Xue; Yongqiang Chen; Mohanad Aldarouish; Hong-Ming Hu; Xue-Jun Zhu; Ning Pan; Li-Xin Wang
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

Review 8.  Myeloid-derived suppressor cells coming of age.

Authors:  Filippo Veglia; Michela Perego; Dmitry Gabrilovich
Journal:  Nat Immunol       Date:  2018-01-18       Impact factor: 25.606

9.  Neutrophils support lung colonization of metastasis-initiating breast cancer cells.

Authors:  Stefanie K Wculek; Ilaria Malanchi
Journal:  Nature       Date:  2015-12-09       Impact factor: 49.962

10.  Ascites promotes cell migration through the repression of miR-125b in ovarian cancer.

Authors:  Lan Yang; Xiaoli Zhang; Yiming Ma; Xinhua Zhao; Bin Li; Hongying Wang
Journal:  Oncotarget       Date:  2017-04-05
View more
  43 in total

Review 1.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

Review 2.  Therapeutic targeting of neutrophil exocytosis.

Authors:  Sergio D Catz; Kenneth R McLeish
Journal:  J Leukoc Biol       Date:  2020-01-28       Impact factor: 4.962

3.  Circulating CD14+ HLA-DRlo/- monocytic cells as a biomarker for epithelial ovarian cancer progression.

Authors:  Ashley E Stenzel; Scott I Abrams; Janine M Joseph; Ellen L Goode; Joseph D Tario; Paul K Wallace; Divjot Kaur; Anna-Kay Adamson; Matthew F Buas; Amit A Lugade; Angela Laslavic; Sarah E Taylor; Brian Orr; Robert P Edwards; Esther Elishaev; Kunle Odunsi; Jennifer M Mongiovi; John Lewis Etter; Stacey J Winham; Scott H Kaufmann; Francesmary Modugno; Kirsten B Moysich
Journal:  Am J Reprod Immunol       Date:  2020-09-21       Impact factor: 3.886

Review 4.  MDSC: Markers, development, states, and unaddressed complexity.

Authors:  Samarth Hegde; Andrew M Leader; Miriam Merad
Journal:  Immunity       Date:  2021-05-11       Impact factor: 31.745

5.  Identification of seven novel ferroptosis-related long non-coding RNA signatures as a diagnostic biomarker for acute myeloid leukemia.

Authors:  Zhiyuan Zheng; Wei Wu; Zehang Lin; Shuhan Liu; Qiaoqian Chen; Xiandong Jiang; Yan Xue; Donghong Lin
Journal:  BMC Med Genomics       Date:  2021-09-27       Impact factor: 3.063

Review 6.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

Review 7.  Specialized immune responses in the peritoneal cavity and omentum.

Authors:  Mingyong Liu; Aaron Silva-Sanchez; Troy D Randall; Selene Meza-Perez
Journal:  J Leukoc Biol       Date:  2020-09-02       Impact factor: 4.962

8.  Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.

Authors:  Hee-Sung Ahn; Jung Yoon Ho; Jiyoung Yu; Jeonghun Yeom; Sanha Lee; Soo Young Hur; Yuyeon Jung; Kyunggon Kim; Youn Jin Choi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

9.  The Prognostic Value of Preoperative Systemic Inflammatory Response Index (SIRI) in Patients With High-Grade Glioma and the Establishment of a Nomogram.

Authors:  Qian He; Longhao Li; Qinglan Ren
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

10.  Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.

Authors:  Haijing Deng; Anna Kan; Ning Lyu; Meng He; Xin Huang; Shuang Qiao; Shaolong Li; Wenhua Lu; Qiankun Xie; Huiming Chen; Jinfa Lai; Qifeng Chen; Xiongying Jiang; Shousheng Liu; Zhenfeng Zhang; Ming Zhao
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.